Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Effect of StentBoost imaging guided percutaneous coronary intervention on mid-term angiographic and clinical outcomes

Authors
Oh, Dong JooChoi, Cheol UngKim, SunWonIm, Sung IlNa, Jin OhLim, Hong EuyKim, Jin WonKim, Eung JuHan, Seong WooRha, Seung-WoonPark, Chang GyuSeo, Hong Seog
Issue Date
30-Sep-2013
Publisher
ELSEVIER IRELAND LTD
Keywords
StentBoost; Percutaneous coronary intervention; Clinical outcomes
Citation
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.168, no.2, pp.1479 - 1484
Indexed
SCIE
SCOPUS
Journal Title
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume
168
Number
2
Start Page
1479
End Page
1484
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/102122
DOI
10.1016/j.ijcard.2012.12.051
ISSN
0167-5273
Abstract
Introduction: The gold standard for evaluating stent expansion after percutaneous coronary intervention (PCI) is intravascular ultrasound (IVUS). However, the routine use of this modality is costly and time consuming. StentBoost is a new imaging technique that improves fluoroscopy-based assessments of stent expansion. The purpose of this study was to evaluate the effect of StentBoost imaging-guided PCI on mid-term angiographic and clinical outcomes. Methods and results: A total of 870 consecutive patients were recruited (mean age: 64.34 +/- 11.61; men: 64.5%), all of whom underwent PCI with drug-eluting stents (DESs). The subjects were divided into a no StentBoost group (n=569 patients) and a StentBoost group (n=301 patients). The 6-month angiographic and 12-month clinical outcomes were compared between the two groups. At 1 month, clinical outcomes were similar between the two groups. At 6 months, the StentBoost group had significantly lower rates of late loss (0.32 +/- 0.40 vs. 0.48 +/- 0.59; p=0.005) and binary restenosis (1.2% vs. 8.3%; p=0.029) compared with the no-StentBoost group. At 12 months, StentBoost group had significantly lower the incidence of target lesion revascularization (TLR) (1.7% vs. 7%; p=0.034) and TLR-major adverse cardiac events (6% vs. 13.2%; p=0.037) compared with the no-StentBoost group. Conclusion: We conclude that the routine clinical use of StentBoost during PCI can be useful, and results in better medium-term angiographic and clinical outcomes. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Jin Won photo

Kim, Jin Won
Department of Biomedical Sciences
Read more

Altmetrics

Total Views & Downloads

BROWSE